The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global anti-rheumatics market reached a value of US$ 61.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 72.1 Billion by 2027, exhibiting at a CAGR of 2.74% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Anti-rheumatics refers to drugs used to treat different symptoms of rheumatoid arthritis. These drugs are also utilized for treating inflammatory myositis and bowel diseases, various types of cancers, and connective tissue diseases, such as systemic sclerosis (SSc), systematic lupus erythematosus (SLE), and Sjogren syndrome (SS). They can be administered orally, subcutaneously (SC) or intravenously (IV) into the body. They assist in decreasing inflammation, preventing joint damage, reducing pain and swelling, and slowing the progression of arthritis. As a result, anti-rheumatics are increasingly being prescribed by specialists like rheumatologists, gastroenterologists or dermatologists across the globe.
Rheumatoid arthritis is an inflammatory disease that causes swelling and pain in joints. It can also damage the skin, eyes, lungs, heart, and blood vessels. Therefore, the increasing prevalence of this medical condition represents one of the primary factors catalyzing the demand for anti-rheumatics around the world. These drugs aid in preventing bone deformity and improving overall body functions. As a result, their demand is escalating among the geriatric population, which is relatively more prone to these diseases. Furthermore, the growing development in the field of biosimilars and novel biologic therapies are creating a favorable market outlook. These therapies target individual molecules and act faster compared to conventional drugs. They are usually provided in combination with the disease-modifying anti-rheumatic drug (DMARD) to patients who have not responded to other treatments. The market is also influenced by the rising awareness among the masses about the easy availability of anti-rheumatics worldwide. Other significant factors, including a considerable rise in healthcare expenditure and extensive growth in the life sciences industry, are projected to drive the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-rheumatics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, drug class, route of drug administration and distribution channel.
Breakup by Type:
Breakup by Drug Class:
Breakup by Route of Drug Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company, Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnsons, Pfizer Inc. and Sanofi SA.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Drug Class, Route of Drug Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company, Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnsons, Pfizer Inc. and Sanofi SA|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at